Q-omics provides the consensus-scored HHLA3 profile across patient tissues and cancer cell-line models. HHLA3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, HHLA3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, HHLA3 RNA expression shows 16,966 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KICH, and TGCT as cancer lineages where HHLA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HHLA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HHLA3 survival associations across molecular data types. HHLA3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HHLA3 RNA expression–survival associations across cancer types. High HHLA3 expression shows unfavorable associations in UCS, KIRC, LGG and HNSC, but favorable associations in UVM and CESC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for HHLA3 RNA expression.
This table summarizes HHLA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HHLA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HHLA3 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LUAD, LIHC and COAD. The KICH box plot shows higher HHLA3 RNA expression in normal versus tumor tissue (log2 FC = −3.020, t-test p < 0.001).
This table shows molecular features associated with HHLA3 in patient tissues and cancer cell lines. In patient samples, HHLA3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HHLA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
